Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

21,396 total articles

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

NRx Pharmaceuticals announced that its subsidiary, HOPE Therapeutics, has become the first commercial site to use Zeta Surgical's FDA-cleared Zeta TMS Navigation System at its West Palm Beach clinic. The system integrates AI-powered, sub-millimetric image guidance to improve precision in Transcranial Magnetic Stimulation (TMS) treatment for major d…

Sharps Technology Becomes SkyAI, Inc. with New Ticker Symbol “SKYA”; Establishing Category-defining Agentic Finance Platform Serving Global South

Sharps Technology Becomes SkyAI, Inc. with New Ticker Symbol “SKYA”; Establishing Category-defining Agentic Finance Platform Serving Global South

Sharps Technology, Inc. has rebranded to SkyAI, Inc. and will trade on Nasdaq under the ticker 'SKYA'. The company is transitioning into building a category-defining agentic finance platform aimed at serving the Global South—emerging markets in Asia, Latin America, and Africa. SkyAI plans to leverage AI, stablecoins, and the Solana blockchain to pr…

Statement from the Supervisory Board of STMicroelectronics

Statement from the Supervisory Board of STMicroelectronics

Following the 2026 Annual General Meeting in Amsterdam, STMicroelectronics appointed Mr. Armando Varricchio as Chairman and Mr. Nicolas Dufourcq as Vice-Chairman of its Supervisory Board, with terms lasting until 2029. The company continues to emphasize its commitment to semiconductor innovation and sustainability goals, including carbon neutrality…

Bath & Body Works Reports First Quarter Results Exceeding Guidance and Progress Against the Consumer First Formula

Bath & Body Works Reports First Quarter Results Exceeding Guidance and Progress Against the Consumer First Formula

Bath & Body Works reported first quarter 2026 net sales of $1.4 billion, a 3% decline year-over-year, with adjusted earnings per share of $0.32 exceeding guidance. The company reaffirmed full-year 2026 guidance projecting net sales decline between 4.5% to 2.5% and adjusted EPS between $2.40 and $2.65. Leadership changes include CFO Eva Boratto step…

Scorpio Tankers Inc. Announces Agreements to Sell Four LR2 Product Tankers, a Letter of Intent to Purchase Two Newbuilding MRs and its Intention to Repay All Secured Debt Due 2028

Scorpio Tankers Inc. Announces Agreements to Sell Four LR2 Product Tankers, a Letter of Intent to Purchase Two Newbuilding MRs and its Intention to Repay All Secured Debt Due 2028

Scorpio Tankers Inc. has entered agreements to sell four LR2 product tankers for $285.8 million and signed a letter of intent to purchase two scrubber-fitted MR product tankers, expected for delivery in 2030. Additionally, the company plans to prepay approximately $367.8 million of secured debt due in 2028, leading to the termination of several cre…

Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

Apogee Therapeutics announced a strategic financing collaboration with Blackstone Life Sciences, gaining up to $1.3 billion in flexible, non-dilutive capital to support the late-stage development and commercialization of its leading product candidate, Zumilokibart, targeting moderate-to-severe atopic dermatitis and other inflammatory and immunology…

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics announced highly positive 16-week results from Part B of its Phase 2 APEX clinical trial evaluating Zumilokibart, an anti-IL-13 antibody, in patients with moderate-to-severe atopic dermatitis. The trial met all primary and secondary endpoints with strong statistical significance, demonstrating robust efficacy and a favorable saf…

PDD Holdings Announces First Quarter 2026 Unaudited Financial Results

PDD Holdings Announces First Quarter 2026 Unaudited Financial Results

PDD Holdings Inc. announced its unaudited financial results for Q1 2026, showing an 11% increase in total revenues to RMB106.2 billion (US$15.4 billion) and a 22% increase in operating profit to RMB19.6 billion (US$2.8 billion) compared to the same quarter in 2025. Despite these gains, net income attributable to ordinary shareholders declined by 15…

Nano Dimension Announces Sale of MarkForged, Inc. to Stratasys

Nano Dimension Announces Sale of MarkForged, Inc. to Stratasys

Nano Dimension has entered into a definitive agreement to sell its wholly owned subsidiary MarkForged, Inc. to Stratasys Ltd. in an all-cash transaction worth $42.5 million. This sale is a key part of Nano Dimension's three-phase strategic plan aimed at maximizing long-term shareholder value. The transaction is expected to reduce Nano Dimension's a…

Radware Reports Results of 2026 Annual General Meeting

Radware Reports Results of 2026 Annual General Meeting

Radware Ltd., a NASDAQ-listed leader in application security and delivery for multi-cloud environments, reported that all three proposals submitted at its 2026 Annual General Meeting were approved by shareholders. The company reaffirmed its leadership in AI-driven cybersecurity solutions and outlined the usual risks and forward-looking statements r…

Enerflex Ltd. Publishes 2026 Investor Update Presentation

Enerflex Ltd. Publishes 2026 Investor Update Presentation

Enerflex Ltd. has published its 2026 Investor Update presentation focusing on its strategy to prioritize operational excellence, targeted growth in attractive natural gas and power markets, and disciplined capital allocation. The company aims to improve adjusted EBITDA margin, cash conversion ratio, and ROCE by over 200 basis points over a full cyc…

Colliers completes acquisition of Ayesa Engineering

Colliers completes acquisition of Ayesa Engineering

Colliers has successfully acquired Ayesa Engineering, a global multidisciplinary engineering and project management firm based in Spain. This acquisition boosts Colliers Engineering's workforce to over 11,000 professionals across 23 countries and enhances its capabilities in property, infrastructure, water, and environmental sectors. The move under…

Agomab Announces Results of Annual General Meeting

Agomab Announces Results of Annual General Meeting

Agomab Therapeutics NV, a clinical-stage biopharmaceutical company listed on Nasdaq, announced at its Annual General Meeting on May 26, 2026, that all agenda items were approved, including approval of financial statements for 2025, discharge of board members and auditors, and reappointments to the Board of Directors. The company focuses on developi…

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

Aligos Therapeutics announced positive Phase 1 long-term follow-up data for pevifoscorvir sodium, demonstrating sustained reduction in hepatitis B viral markers and potential reduction of the cccDNA reservoir. Additionally, preclinical data showed synergistic antiviral effects with the ASO ALG-170675, supporting development of functional cure regim…

argenx to Present at Upcoming Investor Conferences

argenx to Present at Upcoming Investor Conferences

argenx announced its participation in two prominent investor conferences in June 2026, including the William Blair 46th Annual Growth Stock Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The presentations will highlight the company’s progress in immunology and its pipeline of novel antibody-based medicines targeting seve…